Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.

[1]  David T. W. Jones,et al.  N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. , 2018, Neuro-oncology.

[2]  Raymond Y Huang,et al.  Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma , 2018, Neuro-oncology.

[3]  David T. W. Jones,et al.  Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma , 2018, Neuro-oncology.

[4]  H R Jäger,et al.  Glioma imaging in Europe: A survey of 220 centres and recommendations for best clinical practice , 2018, European Radiology.

[5]  O. Andronesi,et al.  Radiomics, Metabolic, and Molecular MRI for Brain Tumors , 2018, Seminars in Neurology.

[6]  Martin Klein,et al.  Lomustine and Bevacizumab in Progressive Glioblastoma , 2017, The New England journal of medicine.

[7]  Klaus H. Maier-Hein,et al.  Brain Tumor Segmentation and Radiomics Survival Prediction: Contribution to the BRATS 2017 Challenge , 2017, BrainLes@MICCAI.

[8]  T. Cloughesy,et al.  Detection of immune responses after immunotherapy in glioblastoma using PET and MRI , 2017, Proceedings of the National Academy of Sciences.

[9]  Susan M. Chang,et al.  Response Assessment in Neuro-Oncology Clinical Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Vernhout,et al.  Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab—a report from the BELOB trial , 2017, Neuro-oncology.

[11]  B. Erickson,et al.  Where size matters: imaging-based biomarkers for patient stratification. , 2017, Neuro-oncology.

[12]  M. Götz,et al.  Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response , 2016, Clinical Cancer Research.

[13]  Jacoline E. C. Bromberg,et al.  Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma. , 2016 .

[14]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[15]  Jian Sun,et al.  Identity Mappings in Deep Residual Networks , 2016, ECCV.

[16]  Dewen Yang.  Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria. , 2016, Neuro-oncology practice.

[17]  Naoya Hashimoto,et al.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.

[18]  Brian B. Avants,et al.  The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS) , 2015, IEEE Transactions on Medical Imaging.

[19]  Marion Smits,et al.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. , 2015, Neuro-oncology.

[20]  P. Sedgwick,et al.  Interpreting hazard ratios , 2015, BMJ : British Medical Journal.

[21]  Thomas Brox,et al.  U-Net: Convolutional Networks for Biomedical Image Segmentation , 2015, MICCAI.

[22]  C. Filippi,et al.  Semiautomated Volumetric Measurement on Postcontrast MR Imaging for Analysis of Recurrent and Residual Disease in Glioblastoma Multiforme , 2014, American Journal of Neuroradiology.

[23]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[24]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[25]  W. Wick,et al.  Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials , 2013, Neuro-oncology.

[26]  A Gregory Sorensen,et al.  Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. , 2013, Neuro-oncology.

[27]  J. Crowley,et al.  Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors , 2013, Clinical Cancer Research.

[28]  L Junck,et al.  Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. , 2011, The Lancet. Oncology.

[29]  Carmine Zoccali,et al.  Statistical methods for the assessment of prognostic biomarkers (Part I): discrimination. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Wen,et al.  Response criteria for glioma , 2008, Nature Clinical Practice Oncology.

[32]  Guido Gerig,et al.  User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability , 2006, NeuroImage.

[33]  A G Sorensen,et al.  Comparison of diameter and perimeter methods for tumor volume calculation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.